Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boyan-I
- Development stage
- Unknown
- Lead developer
- Probionic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Boyan-I is a probiotic dietary supplement developed by the South Korean biotechnology company Probionic. The product's core component is the patented strain *Lactobacillus sakei* Probio65™, which was originally isolated from traditional Korean kimchi. Boyan-I is primarily marketed for the management of skin conditions, specifically atopic dermatitis, by leveraging the 'gut-skin axis' to modulate immune responses. Clinical and preclinical studies associated with the Probio65 strain indicate its ability to reduce the production of pro-inflammatory cytokines (such as IL-4 and IL-13) and lower serum IgE levels, thereby alleviating allergic inflammation. While it is categorized as a functional food or nutraceutical rather than a pharmaceutical drug, it is widely used as a complementary approach for improving skin health and immune balance.
- Brand names
- Boyan-I
- Other names
- Lactobacillus sakei Probio65Boyan-I Probionic
02
Targets
IL-4 (Interleukin 4)IL-13 (Interleukin-13)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Boyan-I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boyan-I.